Prostamax
Also known as: Peptídeo prostático, KEDP
Molecular Identifiers
Overview
Prostatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in prostatic tissue and supports prostate cellular function. Used in short cycles for prostate health protection and maintenance.
Interest around Prostamax centers on support for male prostate health — maintenance of glandular function, modulation of cell proliferation, and normalization of prostatic tissue metabolism in aging contexts. It is positioned as a bioregulatory adjunct, not as a specific treatment for benign prostatic hyperplasia, prostatitis, or prostate cancer.
It has no drug approval from the FDA, EMA, or ANVISA. It circulates through compounding pharmacies and bioregulatory medicine channels, in short cycles of 10-20 days repeated 2-4 times per year, often combined with other Khavinson peptides in longitudinal protocols for men over 40-50.
It belongs to the line of short tetrapeptides developed by the group of Russian researcher Vladimir Khavinson, originally derived from bovine prostatic tissue extracts. The evidence base is predominantly Russian, with modern human clinical trials still scarce.
Within the Khavinson family, Prostamax represents the male prostatic niche, in parallel with Testagen (testicular/HPG, urogenital axis): both are distinguished less by overall mechanism (tissue-specific gene expression regulation) and more by proposed target tissue, with Prostamax focused specifically on the prostate gland. All of this comparative literature is largely Russian and preclinical.
KEDP Lys-Glu-Asp-Pro Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in prostatic tissue
- Support for cellular function and prostate homeostasis
- Normalization of prostatic tissue metabolism
- Modulation of prostatic cell proliferation
- Bioregulatory effect on the prostate gland
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Very stable tetrapeptide. Protect from light and moisture. |
Presentations & Preparation
Vials of Prostamax found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Prostamax.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals